Reactivity of CD8+ T cells from healthy donors and patients with CML before and after SCT to test peptides
. | CMV . | . | . | PR1 . | . | . | WT1 . | . | . | BCR-ABL . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | ||||||||
| Healthy donors | ||||||||||||||||||||
| 1 | —* | — | — | 1298 | ND | — | — | — | — | — | ND | — | ||||||||
| 2 | 62 | ND | 75 | 29 | 17 | 6 | 2 | 2 | — | — | — | — | ||||||||
| 3 | — | — | — | 13 | 2 | — | ND | 5 | 6 | — | — | — | ||||||||
| 4 | — | ND | ND | 2 | — | — | — | — | — | — | ND | — | ||||||||
| 5 | — | ND | ND | — | ND | 2 | — | ND | — | — | ND | — | ||||||||
| 6 | 24 | ND | 18 | — | — | — | — | — | — | ND | ND | ND | ||||||||
| 7 | — | — | — | — | — | — | 16 | 370 | 1067 | — | — | — | ||||||||
| 8 | 23 | ND | ND | — | — | — | — | ND | 2 | — | — | — | ||||||||
| 9 | — | ND | ND | — | ND | — | 5 | ND | 2 | ND | ND | ND | ||||||||
| 10 | 10 | ND | ND | — | — | — | — | — | — | — | — | — | ||||||||
| 11 | 10 | ND | ND | — | — | — | — | — | — | — | — | — | ||||||||
| 12 | 108 | ND | 87 | — | — | — | — | — | — | — | — | — | ||||||||
| 13 | 2339 | ND | 5935 | — | — | — | — | — | — | ND | ND | ND | ||||||||
| 14 | 20 303 | ND | 5805 | — | — | — | — | — | — | ND | ND | ND | ||||||||
| 15 | — | — | — | — | — | — | — | — | ND | ND | ND | ND | ||||||||
| 16 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| 17 | — | ND | ND | — | — | 76 | — | — | — | — | — | — | ||||||||
| 18 | 8.2 | ND | ND | 2.3 | — | — | — | — | — | — | — | — | ||||||||
| Patients with CML before SCT | ||||||||||||||||||||
| 16 | — | ND | ND | — | ND | — | — | ND | — | — | ND | — | ||||||||
| 17 | — | ND | ND | — | ND | 145 | 175 | ND | — | ND | ND | ND | ||||||||
| 25 | — | ND | ND | — | — | — | — | — | 152 | ND | ND | ND | ||||||||
| 38 | — | ND | ND | 4 | — | 4 | 4 | — | 4 | ND | ND | ND | ||||||||
| 41 | — | ND | ND | 3 | ND | — | — | ND | 8 | — | — | — | ||||||||
| 181 | — | ND | ND | — | — | 3.2 | — | — | — | — | — | — | ||||||||
| 199 | — | ND | ND | — | 323 | ND | — | 237 | ND | ND | ND | ND | ||||||||
| 210 | — | — | — | 615 | 136 | 156 | — | 336 | — | — | 34 | 216 | ||||||||
| 241 | 42 | 32 | 21 | — | — | — | — | — | — | — | — | — | ||||||||
| 254 | — | ND | ND | 2 | ND | 2 | 2 | ND | 2 | 2 | ND | 2 | ||||||||
| 262 | — | ND | ND | — | ND | — | — | ND | — | — | ND | — | ||||||||
| 283 | 43 | ND | ND | 17 | 11 | 12 | — | — | — | — | — | 2 | ||||||||
| 319 | 24 | 21 | 24 | — | — | — | — | — | — | — | — | — | ||||||||
| 327 | — | ND | ND | — | ND | — | — | ND | — | ND | ND | ND | ||||||||
| Patients with CML after SCT | ||||||||||||||||||||
| 181 | 8.5 | ND | ND | — | 2.5 | — | — | 2.1 | — | — | ND | 2.0 | ||||||||
| 210 | 1133 | ND | 1712 | 9643 | — | — | ND | 684 | 9 | — | — | — | ||||||||
| 223 | — | ND | ND | — | — | — | — | — | — | — | ND | 2.5 | ||||||||
| 283 | — | ND | ND | — | ND | — | — | ND | — | — | ND | — | ||||||||
| 327, day 100 | 53 | ND | ND | — | — | — | — | ND | 136 | 2.5 | ND | 2.5 | ||||||||
| 327, day 360 | 41 | ND | ND | — | — | — | — | — | — | — | — | 29 | ||||||||
| 319 | 2 | 7417 | 9 | — | 3 | — | 3 | — | — | — | 3.5 | — | ||||||||
. | CMV . | . | . | PR1 . | . | . | WT1 . | . | . | BCR-ABL . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPN . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | 0.1 μM . | 1 μM . | 10 μM . | ||||||||
| Healthy donors | ||||||||||||||||||||
| 1 | —* | — | — | 1298 | ND | — | — | — | — | — | ND | — | ||||||||
| 2 | 62 | ND | 75 | 29 | 17 | 6 | 2 | 2 | — | — | — | — | ||||||||
| 3 | — | — | — | 13 | 2 | — | ND | 5 | 6 | — | — | — | ||||||||
| 4 | — | ND | ND | 2 | — | — | — | — | — | — | ND | — | ||||||||
| 5 | — | ND | ND | — | ND | 2 | — | ND | — | — | ND | — | ||||||||
| 6 | 24 | ND | 18 | — | — | — | — | — | — | ND | ND | ND | ||||||||
| 7 | — | — | — | — | — | — | 16 | 370 | 1067 | — | — | — | ||||||||
| 8 | 23 | ND | ND | — | — | — | — | ND | 2 | — | — | — | ||||||||
| 9 | — | ND | ND | — | ND | — | 5 | ND | 2 | ND | ND | ND | ||||||||
| 10 | 10 | ND | ND | — | — | — | — | — | — | — | — | — | ||||||||
| 11 | 10 | ND | ND | — | — | — | — | — | — | — | — | — | ||||||||
| 12 | 108 | ND | 87 | — | — | — | — | — | — | — | — | — | ||||||||
| 13 | 2339 | ND | 5935 | — | — | — | — | — | — | ND | ND | ND | ||||||||
| 14 | 20 303 | ND | 5805 | — | — | — | — | — | — | ND | ND | ND | ||||||||
| 15 | — | — | — | — | — | — | — | — | ND | ND | ND | ND | ||||||||
| 16 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| 17 | — | ND | ND | — | — | 76 | — | — | — | — | — | — | ||||||||
| 18 | 8.2 | ND | ND | 2.3 | — | — | — | — | — | — | — | — | ||||||||
| Patients with CML before SCT | ||||||||||||||||||||
| 16 | — | ND | ND | — | ND | — | — | ND | — | — | ND | — | ||||||||
| 17 | — | ND | ND | — | ND | 145 | 175 | ND | — | ND | ND | ND | ||||||||
| 25 | — | ND | ND | — | — | — | — | — | 152 | ND | ND | ND | ||||||||
| 38 | — | ND | ND | 4 | — | 4 | 4 | — | 4 | ND | ND | ND | ||||||||
| 41 | — | ND | ND | 3 | ND | — | — | ND | 8 | — | — | — | ||||||||
| 181 | — | ND | ND | — | — | 3.2 | — | — | — | — | — | — | ||||||||
| 199 | — | ND | ND | — | 323 | ND | — | 237 | ND | ND | ND | ND | ||||||||
| 210 | — | — | — | 615 | 136 | 156 | — | 336 | — | — | 34 | 216 | ||||||||
| 241 | 42 | 32 | 21 | — | — | — | — | — | — | — | — | — | ||||||||
| 254 | — | ND | ND | 2 | ND | 2 | 2 | ND | 2 | 2 | ND | 2 | ||||||||
| 262 | — | ND | ND | — | ND | — | — | ND | — | — | ND | — | ||||||||
| 283 | 43 | ND | ND | 17 | 11 | 12 | — | — | — | — | — | 2 | ||||||||
| 319 | 24 | 21 | 24 | — | — | — | — | — | — | — | — | — | ||||||||
| 327 | — | ND | ND | — | ND | — | — | ND | — | ND | ND | ND | ||||||||
| Patients with CML after SCT | ||||||||||||||||||||
| 181 | 8.5 | ND | ND | — | 2.5 | — | — | 2.1 | — | — | ND | 2.0 | ||||||||
| 210 | 1133 | ND | 1712 | 9643 | — | — | ND | 684 | 9 | — | — | — | ||||||||
| 223 | — | ND | ND | — | — | — | — | — | — | — | ND | 2.5 | ||||||||
| 283 | — | ND | ND | — | ND | — | — | ND | — | — | ND | — | ||||||||
| 327, day 100 | 53 | ND | ND | — | — | — | — | ND | 136 | 2.5 | ND | 2.5 | ||||||||
| 327, day 360 | 41 | ND | ND | — | — | — | — | — | — | — | — | 29 | ||||||||
| 319 | 2 | 7417 | 9 | — | 3 | — | 3 | — | — | — | 3.5 | — | ||||||||
Data are presented as stimulation index that corrects the amount of IFN-γ mRNA copy number expressed by CD8+ T cells exposed to relevant peptide over constitutive expression of same cytokine (exposure to unloaded APC) as measured by the direct quantitative, RT-PCR assay. Note: because of limited amount of material not all peptides and concentrations were tested in every case. Patient 327 was tested at 2 time points after SCT, at days 100 and 365. UPN indicates unique patient number; and ND, not done.
Stimulation indices scored as (—) represent reactivities < 2 over background. The — scores for CMV stimulation were seen only in CMV-seronegative individuals.